<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802722</url>
  </required_header>
  <id_info>
    <org_study_id>011280</org_study_id>
    <nct_id>NCT02802722</nct_id>
  </id_info>
  <brief_title>Does Vitamin D Supplementation Enhance Resolution of Inflammation After Community-acquired Pneumonia?</brief_title>
  <acronym>ResolveD-CAP</acronym>
  <official_title>A Prospective Randomised Placebo-controlled Study of the Influence of Vitamin D Supplementation on Resolution of Inflammation Following Community-acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous research has shown that people who have been hospitalised for pneumonia are more&#xD;
      likely to die of conditions such as heart attacks, stroke and cancer in the weeks to months&#xD;
      after their illness. This risk is linked to raised levels of inflammation. Laboratory&#xD;
      research shows that vitamin D can help to clear inflammation. Vitamin D deficiency is very&#xD;
      common in the United Kingdom. The investigators are conducting this study to find out if&#xD;
      taking vitamin D can hasten long-term recovery from pneumonia by reducing inflammation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma IL-6 concentrations</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>IL-6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum CRP</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total white cell count and differential white cell count in induced sputum samples</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>WBC and differential counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune cell phenotypes in peripheral blood</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>flow cytometry phenotypes, blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune cell phenotypes in induced sputum samples</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>flow cytometry phenotypes, induced sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of pro- and anti-inflammatory mediators in peripheral blood</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>Cytokines, lipid mediators, blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of pro- and anti-inflammatory mediators in induced sputum samples</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>Cytokines, lipid mediators, induced sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of pro- and anti-inflammatory mediators in supernatants from whole blood stimulated with antigens ex-vivo</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>Cytokines, lipid mediators, stimulated blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole blood transcriptional profiles</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>mRNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumes of lung abnormalities on chest CT imaging</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>CT data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumonia symptom scores</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>CAP-Sym scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Immediate supplementation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary supplement: Vitamin D3 supplementation - oral capsules 6400 International Units once daily for 6 weeks Peripheral blood and induced sputum sampling Chest computerised tomography (CT) scans Symptom questionnaire</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed supplementation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: oral placebo capsules once daily for 6 weeks Peripheral blood and induced sputum sampling Chest computerised tomography (CT) scans Symptom questionnaire</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 supplementation</intervention_name>
    <description>Capsules to be dispensed using an electronic dispenser to allow real time logging of adherence.</description>
    <arm_group_label>Immediate supplementation</arm_group_label>
    <other_name>cholecalciferol</other_name>
    <other_name>colecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peripheral blood and induced sputum sampling</intervention_name>
    <description>To attain samples for immunological testing</description>
    <arm_group_label>Delayed supplementation</arm_group_label>
    <arm_group_label>Immediate supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chest computerised tomography (CT) scans</intervention_name>
    <description>For volumetric quantification of lung abnormalities</description>
    <arm_group_label>Delayed supplementation</arm_group_label>
    <arm_group_label>Immediate supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Symptom questionnaire</intervention_name>
    <description>Symptom questionnaire for recent symptom history</description>
    <arm_group_label>Delayed supplementation</arm_group_label>
    <arm_group_label>Immediate supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>To be dispensed using an electronic dispenser to allow real time logging of adherence.</description>
    <arm_group_label>Delayed supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults ≥50 years of age&#xD;
&#xD;
          2. Vitamin D deficiency at entry, defined as a serum total 25(OH)D concentration &lt;50&#xD;
             nmol/L&#xD;
&#xD;
          3. Admission to hospital with an acute illness (≤21 days) consistent with&#xD;
             community-acquired pneumonia - at least one symptom of a lower respiratory tract&#xD;
             infection (cough, sputum production, dyspnoea, wheeze, chest discomfort or pain,&#xD;
             fever) and new infiltrate on chest radiograph&#xD;
&#xD;
          4. Adequate mental capacity to give informed consent for participation in the study and&#xD;
             gives written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently taking any vitamin D supplementation&#xD;
&#xD;
          2. Known HIV infection, other condition causing immunosuppression, current&#xD;
             immunosuppressive therapy or systemic corticosteroids&#xD;
&#xD;
          3. Known malignancy not in remission for &gt;3 years or terminal illness with prognosis&#xD;
             &lt;1year&#xD;
&#xD;
          4. History of smoking within the previous 1 year&#xD;
&#xD;
          5. Known or suspected diagnosis of chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
          6. Previous hospitalisation within 10 days of admission&#xD;
&#xD;
          7. Aspiration pneumonia diagnosed by the clinical team&#xD;
&#xD;
          8. Known diagnosis of cystic fibrosis, bronchiectasis or interstitial lung disease at&#xD;
             screening&#xD;
&#xD;
          9. Complications of pneumonia such as empyema or lung abscess at entry&#xD;
&#xD;
         10. Recent acute coronary syndrome within the previous 1 month&#xD;
&#xD;
         11. Long term oxygen therapy, chronic mechanical ventilation dependency or other&#xD;
             contraindication to sputum induction&#xD;
&#xD;
         12. Serum corrected calcium concentration &gt;2.65 mmol/L at entry&#xD;
&#xD;
         13. Chronic kidney disease stage 4-5 (estimated glomerular filtration rate &lt;30ml/min) on&#xD;
             an existing blood sample from the current hospital admission&#xD;
&#xD;
         14. Known clinical diagnosis of liver failure&#xD;
&#xD;
         15. Known or suspected diagnosis of active pulmonary tuberculosis&#xD;
&#xD;
         16. Known diagnosis of primary hyperparathyroidism&#xD;
&#xD;
         17. Known diagnosis of sarcoidosis&#xD;
&#xD;
         18. Known diagnosis of nephrolithiasis&#xD;
&#xD;
         19. Taking carbamazepine, phenytoin, phenobarbital, primidone, cardiac glycosides or&#xD;
             benzothiadiazines with concomitant calcium supplementation at entry&#xD;
&#xD;
         20. Known allergy to vitamin D or its excipients&#xD;
&#xD;
         21. Currently taking part in another research study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Martineau, MBBS</last_name>
    <role>Study Chair</role>
    <affiliation>Queen Mary University of London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alicia D Yeap, MBBS</last_name>
    <phone>(44)7810715924</phone>
    <email>a.d.yeap@qmul.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Yeap, MBBS</last_name>
      <phone>+447810715924</phone>
      <email>a.d.yeap@qmul.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Alicia Yeap, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Yende S, D'Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, Kong L, Carter M, Angus DC; GenIMS Investigators. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med. 2008 Jun 1;177(11):1242-7. doi: 10.1164/rccm.200712-1777OC. Epub 2008 Mar 27.</citation>
    <PMID>18369199</PMID>
  </reference>
  <reference>
    <citation>Remmelts HH, van de Garde EM, Meijvis SC, Peelen EL, Damoiseaux JG, Grutters JC, Biesma DH, Bos WJ, Rijkers GT. Addition of vitamin D status to prognostic scores improves the prediction of outcome in community-acquired pneumonia. Clin Infect Dis. 2012 Dec;55(11):1488-94. doi: 10.1093/cid/cis751. Epub 2012 Aug 31.</citation>
    <PMID>22942205</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>convalescence</keyword>
  <keyword>inflammation</keyword>
  <keyword>resolution</keyword>
  <keyword>vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

